Format

Send to

Choose Destination
J Am Acad Dermatol. 2019 Mar 13. pii: S0190-9622(19)30423-2. doi: 10.1016/j.jaad.2019.03.009. [Epub ahead of print]

Navigating the landscape of core outcome set development in dermatology.

Author information

1
Amsterdam UMC, VU University medical center, Department of Epidemiology and Biostatistics, Amsterdam Public Health research institute, De Boelelaan 1089a, 1081 HV Amsterdam, the Netherlands.
2
Amsterdam UMC, University of Amsterdam, Department of Dermatology, Amsterdam Public health, Infection and Immunity, Meibergdreef 9, Amsterdam, The Netherlands.
3
Charité-Universitätsmedizin Berlin, Department of Dermatology and Allergy, Germany; University Centre for Nursing and Midwifery, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium. Electronic address: jan.kottner@charite.de.
4
Centre of Evidence Based Dermatology, University of Nottingham, King's Meadow Campus, Lenton Lane, Nottingham, NG7 2NR, United Kingdom.
5
Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
6
Center for Evidene-based Healthcare, Medical Faculty Carl Gustav Carus, TU Dresden, Germany.
7
Department of Dermatology, Kyushu University, Fukuoka, Japan.
8
MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Liverpool, United Kingdom.
9
Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A.
10
Department of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
11
Institute for Social Medicine and Epidemiology, University of Lübeck, Germany.
12
University Centre for Nursing and Midwifery, Department of Public Health and Primary Care, Ghent University, Ghent, Belgium.
13
Department of Dermatology and Evaluation of Therapeutics (EpiDermE), EA7379, Paris-Est University, UPEC, DHU VIC, Créteil, France.
14
Amsterdam UMC, University of Amsterdam, Department of Plastic, Reconstructive and Hand Surgery, Meibergdreef 9, Amsterdam, The Netherlands.
15
Division of Infection & Immunity, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, United Kingdom.
16
Hull York Medical School, University of York, Heslington, York, YO10 5DD; Harrogate & District NHS Foundation Trust, Lancaster Park Road, Harrogate, HG2 7SX, United Kingdom.
17
Charité-Universitätsmedizin Berlin, Department of Dermatology and Allergy, Germany.
18
Department of Plastic, Aesthetic and Hand Surgery, Interdisciplinary Center for Treatment of Chronic Wounds, Dessau Medical Center Dessau, Germany; Department of Dermatology, Venereology, Allergology and Immunology,Dessau Medical Center, Brandenburg Medical School Theodore Fontane, Germany; Institut of Applied Bio-Sciences and Process Management, University of Applied Science Anhalt, Bernburger Strasse 55, 06354 Koethen, Germany.

Abstract

The development of core outcome sets (COS), i.e. a minimum set of 'core outcomes' that should be measured and reported in all trials or clinical practice of a specific condition, in dermatology is gathering pace. A total of 44 dermatology-related COS projects have been registered in the online Core Outcome Measures in Effectiveness Trials (COMET) database (http://www.comet-initiative.org/studies/search), and include studies on 26 different skin diseases. With the increasing number of COS in dermatology, care is needed to ensure the delivery of high quality COS that meet quality standards based on state of the art methodology. In 2015, the Cochrane Skin - Core Outcome Set Initiative (CS-COUSIN) was established. CS-COUSIN is an international, multidisciplinary working group, aiming to improve the development and implementation of COS in dermatology. CS-COUSIN has developed guidance on how to develop high quality COS for skin diseases, and supports dermatology-specific COS initiatives. Currently, 16 COS development groups are affiliated to CS-COUSIN following standardized COS development processes. To ensure successful uptake of COS in dermatology, researchers, clinicians, systematic reviewers, guideline developers and other stakeholders should use existing COS in their work.

KEYWORDS:

CS-COUSIN; Cochrane Skin; Dermatology; clinical trials; core outcome set; development; implementation

PMID:
30878565
DOI:
10.1016/j.jaad.2019.03.009

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center